Get the Stockscreener App
7.87
1.87%
-0.15
After Hours:
7.87
Biocryst Pharmaceuticals Inc stock is traded at $7.87, with a volume of 2.22M.
It is down -1.87% in the last 24 hours and up +4.52% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$8.02
Open:
$8.08
24h Volume:
2.22M
Relative Volume:
1.02
Market Cap:
$1.63B
Revenue:
$331.41M
Net Income/Loss:
$-226.54M
P/E Ratio:
-6.6695
EPS:
-1.18
Net Cash Flow:
$-97.31M
1W Performance:
+1.81%
1M Performance:
+4.52%
6M Performance:
+6.35%
1Y Performance:
+43.09%
1-Day Range:
$7.80
$8.14
1-Week Range:
$7.53
$8.14
52-Week Range:
$4.03
$8.88
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Industry
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.87 | 1.63B | 331.41M | -226.54M | -97.31M | -1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
Trading (BCRX) With Integrated Risk Controls - Stock Traders Daily
Fibrodysplasia Ossificans Progressiva Market Set to Grow Substantially Through 2032, DelveInsight Projects | Ipsen, Regeneron Pharmaceutical, Biocryst - Barchart
Fibrodysplasia Ossificans Progressiva Market Set to Grow - openPR
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 5.6%Still a Buy? - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Inspire Investing LLC - MarketBeat
Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Immatics (NASDAQ:IMTX) - Defense World
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $15.17 Average PT from Brokerages - MarketBeat
HRMY: 3 Under-the-Radar Biotech Stocks Revolutionizing Healthcare - StockNews.com
Trend Tracker for (BCRX) - Stock Traders Daily
JPMorgan Chase & Co. Decreases Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Significant Drop in Short Interest - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Significant Decline in Short Interest - Defense World
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 3.4%Time to Sell? - MarketBeat
BioCryst releases preliminary 2024 results, 2025 guidance - MSN
Be Bio secures $92m for haemophilia B and hypophosphatasia treatments - Pharmaceutical Technology
Evercore ISI Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - Defense World
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - Defense World
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Down 3.4%Time to Sell? - MarketBeat
BioCryst price target raised to $12 from $10 at Evercore ISI - Yahoo Finance
BioCryst's SWOT analysis: stock outlook amid orladeyo's growth and pipeline shifts - Investing.com
BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $12.00 - MarketBeat
BioCryst to Present at J.P. Morgan Conference - TipRanks
BioCryst Pharmaceuticals Releases Positive Financial Results and Guidance for 2025 - Defense World
BioCryst Pharmaceuticals Increases Wholesale Acquisition Cost for ORLADEYO®BioCryst Pharmaceuticals, Inc. has announced an increase in the wholesale acquisition cost (WAC) for ORLADEYO®, a medication used to treat various conditions in the United - Defense World
BioCryst stock target raised to $12 at Evercore ISI By Investing.com - Investing.com Canada
BioCryst projects $515-$535 million in ORLADEYO sales for 2025 By Investing.com - Investing.com Australia
Exploring High Growth Tech Stocks In January 2025 - Simply Wall St
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap UpShould You Buy? - MarketBeat
BioCryst projects $515-$535 million in ORLADEYO sales for 2025 - Investing.com India
BioCryst Projects Strong Revenue Growth in 2024-2025 - TipRanks
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) - The Manila Times
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® - GlobeNewswire
BioCryst adjusts price of ORLADEYO in the U.S. By Investing.com - Investing.com Australia
Objective long/short (BCRX) Report - Stock Traders Daily
BioCryst adjusts price of ORLADEYO in the U.S. - Investing.com
BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
BioCryst Pharmaceuticals to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Cutaneous T-cell Lymphoma Market on Track for Major Expansion - openPR
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Awards Stock Options and RSUs to New Hires in Talent Acquisition Push - StockTitan
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Principal Financial Group Inc. - MarketBeat
Principal Financial Group Inc. Acquires 375,890 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Down 10.7% in December - MarketBeat
BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4161 for the Treatment of Hereditary - AOL
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
BioCryst Pharmaceuticals Insiders Added US$1.05m Of Stock To Their Holdings - Simply Wall St
The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127% - Yahoo Finance
Franklin Resources Inc. Acquires 168,790 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
T-cell Lymphoma Market Key Players Analysis4SC AG, Acrotech - openPR
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by Geode Capital Management LLC - MarketBeat
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):